title: Corticotropin-releasing factor receptor type 2 messenger ribonucleic acid in rat pituitary: localization and regulation by immune challenge, restraint stress, and glucocorticoids.
abstract: CRF receptor 2 (CRF R2) has been identified in the rat pituitary. However, the cell types that express the receptor remained to be determined. In the present study, we localized CRF R2 mRNA in gonadotropes of the anterior pituitary. Ribonuclease protection assays of anterior pituitary mRNA further showed that the dominant receptor type is CRF R2alpha. We also demonstrated that the expression of CRF R2 in the pituitary is sensitive to alterations to the hypothalamic-pituitary-adrenal axis as CRF R2 mRNA levels in the anterior pituitary of male rats were significantly decreased 6 h after bacterial endotoxin lipopolysaccharide (LPS) injection or restraint stress. Subcutaneous corticosterone injections also resulted in significant suppression of CRF R2 mRNA levels in the pituitary, suggesting that glucocorticoids are involved in modulating CRF R2 mRNA levels in the pituitary under stress. LPS administration still caused a significant suppression of CRF R2 mRNA levels in the anterior pituitary of adrenalectomized rats. This suggests that one or more additional factors is involved in the regulation of CRF R2 expression in the anterior pituitary. Taken together, these data suggest that CRF R2alpha in the anterior pituitary might be involved in the regulation of gonadal functions under stress.
authors.affiliation: The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California 92037, USA.
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kageyama
authors.forename: Chien
authors.initials: C
authors.lastname: Li
authors.forename: Wylie W
authors.initials: WW
authors.lastname: Vale
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D003345:Corticosterone / Q000494:pharmacology; D015870:Gene Expression / Q000276:immunology; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D007279:Injections, Subcutaneous; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D015213:Neuroimmunomodulation / Q000502:physiology; D010903:Pituitary Gland, Anterior / Q000276:immunology / Q000503:physiopathology*; D010913:Pituitary-Adrenal System / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000235:genetics*; D012149:Restraint, Physical; D013312:Stress, Physiological / Q000276:immunology / Q000503:physiopathology*
chemical_list: D000893:Anti-Inflammatory Agents; C101531:CRF receptor type 2; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D018019:Receptors, Corticotropin-Releasing Hormone; D003345:Corticosterone